Denis Guttridge to Treatment Outcome
This is a "connection" page, showing publications Denis Guttridge has written about Treatment Outcome.
Connection Strength
0.035
-
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017; 12(7):e0181885.
Score: 0.016
-
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease. Pancreas. 2013 Jul; 42(5):813-8.
Score: 0.012
-
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006 Apr 20; 24(12):1852-9.
Score: 0.007